Pelvic exenteration: a review of the Gateshead experience 1974-1992.
To examine morbidity and survival among women treated by pelvic exenteration for gynaecological malignancy. Retrospective review by analysis of case records. Department of Gynaecological Oncology, Queen Elizabeth Hospital, Gateshead, UK. Eighty-three consecutive patients referred from within the UK from 1974 to 1992 for initial treatment of advanced gynaecological malignancy or management of recurrent disease following unsuccessful initial therapy. Overall five year actuarial survival was 41%, falling to 36% at 10 years. Serious morbidity was low, and there were only three peri-operative deaths. For patients with limited options for treatment of advanced primary or recurrent cancer, exenteration offers a reasonable prospect of survival with good quality of life.